@article{1bd5d19b599f4bac91b1ea955a866cc6,
title = "Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease",
abstract = "LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2%; in CSF, Aβ1-40 decreased by 4.42 ± 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.",
author = "Siemers, {E. R.} and Quinn, {J. F.} and J. Kaye and Farlow, {M. R.} and A. Porsteinsson and P. Tariot and P. Zoulnouni and Galvin, {J. E.} and Holtzman, {D. M.} and Knopman, {D. S.} and J. Satterwhite and C. Gonzales and Dean, {R. A.} and May, {P. C.}",
note = "Funding Information: Disclosure: This study was sponsored by Eli Lilly and Co. Eli Lilly and Co. was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. Drs. Siemers, Satterwhite, Dean, May, and Mr. Gonzales are employees of Eli Lilly and Co. and have an equity or ownership interest in the company. Drs. Quinn, Kaye, Farlow, Porteinsson, Zoulnouni, Galvin, Holtzman, and Knopman have received research support from Eli Lilly and Co. Dr. Farlow has received other research grants for clinical trials from Eli Lilly and Co. in excess of $10,000. ",
year = "2006",
month = feb,
doi = "10.1212/01.WNL.0000198762.41312.E1",
language = "English",
volume = "66",
pages = "602--604",
journal = "Neurology",
issn = "0028-3878",
number = "4",
}